Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Launched by CALIBR, A DIVISION OF SCRIPPS RESEARCH · Jul 22, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Patients will be enrolled following either the completion or early termination/discontinuation from Study NCT04450069 or any protocol in which patients were administered CLBR001. Patients will begin the long-term follow-up period regardless of whether they responded to treatment or progressed on treatment. Patients will be followed for up to 15 years post CLBR001 infusion and will continue to be monitored for safety, immunogenicity, and efficacy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable.
- • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Exclusion Criteria:
- • There are no specific exclusion criteria for this study
About Calibr, A Division Of Scripps Research
Calibr, a division of Scripps Research, is a pioneering biotechnology organization dedicated to advancing the discovery and development of transformative therapies. Leveraging cutting-edge science and innovative technologies, Calibr focuses on translating high-impact research into clinically viable solutions for unmet medical needs. The organization collaborates with academic institutions, industry partners, and clinical investigators to accelerate the progress of novel treatments, particularly in the fields of immunology, oncology, and regenerative medicine. With a commitment to excellence and a patient-centered approach, Calibr aims to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Duarte, California, United States
San Diego, California, United States
Minneapolis, Minnesota, United States
New York, New York, United States
Winston Salem, North Carolina, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials